ArticleDiabetes care2022

Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk.

Jan Westerink et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.